Analysis of the prognostic potential of the genes present in the locus 9p22.1-p21.3 in gliomas

• Grant number: 16/21727-4
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2017
• End date: March 31, 2020
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Lucas Tadeu Bidinotto
• Grantee: Lucas Tadeu Bidinotto
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil
• Associated researchers: Matias Eliseo Melendez ; Rui Manuel Vieira Reis
• Associated scholarship(s): 17/21671-1 - Analysis of the prognostic potential of the genes present in the locus 9p22.1-p21.3 in gliomas, BP.TT

Abstract

Gliomas are the most frequent and malignant brain neoplasias among the central nervous system tumors. Some subtypes are incurable neoplasias, with mean survival of 13 months, and less than 2% of the patients reach 5 years post treatment. The low success in the treatment of these tumors is, in part, due to the lowunderstanding of their molecular bases. Moreover, our research group described a frequently deleted region (chr9p22.1-p21.3) in gliomas, with potentially important genes in prognosis of this neoplasia. Therefore, the objective of the present project isto analyze the prognostic potential of the genes present in chr9p22.1-p21.3 in gliomas. Additionally, we aim to evaluate the functional effects of the loss-ofexpression and reexpression of the genes present in this locus in glioma cell lines. We will analyze the prognostic potential of the 27 genes present in this locus in silico, and will select 2 to 4 genes to posterior analyses. For each gene, we will analyse protein (immunohistochemistry and western blot) and mRNA (qRT-PCR) expression in cell lines and glioma cases from Barretos Cancer Hospital and partners. Based on the results, the genes will be silenced and reexpressed in cell lines, and functional alterations will be evaluated (proliferation, apoptosis, migration and cell invasion). Finally, we will evaluate the response of these manipulated lines to the treatment with drugs. These results may propose novel therapeutical approaches to the treatment of patients with intrinsically present this deletion. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BRUNHARA, BRUNO B.; BECKER, ALINE P.; NEDER, LUCIANO; GONCALVES, PAOLA G.; DE OLIVEIRA, CRISTIANE; CLARA, CARLOS A.; REIS, RUI M.; BIDINOTTO, LUCAS T.. Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas. NEUROPATHOLOGY, NOV 2020. (16/23919-8, 12/19590-0, 17/09749-5, 16/21727-4)

DA COSTA, BRUNO HENRIQUE BRESSAN; BECKER, ALINE PAIXAO; NEDER, LUCIANO; GONCALVES, PAOLA GYULIANE; DE OLIVEIRA, CRISTIANE; POLVERINI, ALLAN DIAS; CLARA, CARLOS AFONSO; TEIXEIRA, GUSTAVO RAMOS; REIS, RUI MANUEL; BIDINOTTO, LUCAS TADEU. EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome. JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, v. N/A, p. 10-pg., 2022-06-15. (18/20737-1, 17/09749-5, 16/21727-4)

GONCALVES, PAOLA G.; REIS, RUI M.; BIDINOTTO, LUCAS T.. Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis. ANTICANCER RESEARCH, v. 42, n. 11, p. 14-pg., 2022-11-01. (17/09749-5, 16/21727-4)

BRUNHARA, BRUNO B.; BECKER, ALINE P.; NEDER, LUCIANO; GONCALVES, PAOLA G.; DE OLIVEIRA, CRISTIANE; CLARA, CARLOS A.; REIS, RUI M.; BIDINOTTO, LUCAS T.. Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas. NEUROPATHOLOGY, v. 41, n. 1, p. 8-pg., 2020-11-15. (16/21727-4, 16/23919-8, 17/09749-5, 12/19590-0)